Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 1/20 | 0.53 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.53 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.53 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.53 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.53 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.50 |
| ▸ | DRD2 | P14416 | 6/20 | 0.47 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.46 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.44 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL82404 | 0.91 | HRH3 (0.59) | GRIN2DGRIN3BMAPTGRIN1GRIN2A | |
| SCHEMBL19389962 | 0.87 | LTA4H (0.57) | HRH3DRD2PSMB1PSMB5SLC6A4 | |
| SCHEMBL12278101 | 0.86 | KMT2A (0.56) | HRH3DRD2PSMB1PSMB5SLC6A4 | |
| SCHEMBL82436 | 0.84 | GRIN2D (0.57) | GRIN2DGRIN3BMAPTGRIN1GRIN2A | |
| SCHEMBL23291189 | 0.81 | HRH3 (0.49) | GRIN2DGRIN3BMAPTGRIN1GRIN2A | |
| SCHEMBL25381352 | 0.79 | TBXAS1 (0.48) | GRIN2DGRIN3BMAPTGRIN1GRIN2A | |
| SCHEMBL25462936 | 0.78 | MAPT (0.64) | GRIN2DGRIN3BMAPTGRIN1GRIN2A | |
| SCHEMBL18069850 | 0.77 | HRH3 (0.57) | MAPTGRIN2BHRH3 | |
| SCHEMBL23291194 | 0.77 | LTA4H (0.43) | GRIN2DGRIN3BMAPTGRIN1GRIN2A | |
| SCHEMBL25464878 | 0.76 | DRD2 (0.80) | GRIN2DGRIN3BMAPTGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | JAK2, TYK2, JAK3 | GRIN2D 2662/4885GRIN3B 1978/4885MAPT 3127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.